Search

A study conducted between 2017 and 2023 analyzed 33 cases of patients, mostly men, aged 20-54, who exhibited various behaviors such as aggression, lethargy, and noncooperation after abusing a range of drugs. The patients had committed offenses and underwent forensic toxicological analyses, revealing the presence of multiple substances in their blood, leading to the conclusion that their behaviors were linked to drug abuse. The study highlighted the toxicities associated with drugs like alprazolam, amitriptyline, amfetamine, and others, emphasizing the importance of understanding the effects of substance abuse on behavior. [Extracted from the article]

A retrospective study described 13 patients, aged 58-90, who developed long QT syndrome while being treated with various drugs such as azithromycin, bepridil, levofloxacin, and others between 2004 and 2020. These patients had underlying heart conditions or had undergone surgery, and all developed long QT syndrome due to the medications. They all experienced atrial arrhythmia and were admitted to the hospital, later developing Torsade de Pointes during ECG monitoring. Treatment with magnesium was administered after stopping the implicated drugs. [Extracted from the article]

A 71-year-old woman developed Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome while being treated for subdural empyema with phenytoin, cefepime, vancomycin, and quetiapine. She presented with altered mental status and later developed a rash, fever, leukocytosis, and hypotension. The diagnosis was confirmed based on lab work and biopsy results, attributing the syndrome to the medications she was taking. Treatment with the implicated drugs was stopped, and she showed improvement after starting prednisone. [Extracted from the article]

The article "Multiple drugs: Various toxicities following in-utero exposure: 5 case reports" in Reactions Weekly discusses five cases of foetuses experiencing adverse effects after in-utero exposure to medications such as citalopram, clonazepam, clonidine, escitalopram, fluoxetine, gabapentin, hydroxyzine, methadone, and quetiapine. The cases describe symptoms like generalised hypertonia, bilateral arm stiffening, sucking mouth movements, decerebrate posturing, and asynchronous tremoring of extremities. The mothers received different combinations of these medications during pregnancy, leading to the observed toxicities in the foetuses. [Extracted from the article]

A case report in the journal "Reactions Weekly" describes a 58-year-old man with paranoid schizophrenia who developed neutropenia while being treated with clozapine. The man also showed lack of efficacy with quetiapine, leading to his admission to a psychiatric unit. Various medications were tried with varying degrees of success, including aripiprazole, lurasidone, and sodium-valproate. Despite some improvements with clozapine rechallenge and electroconvulsive therapy, the man struggled with stress and disturbances, ultimately leading to an extended stay in a psychiatric hospital. [Extracted from the article]

A case report in the journal "Reactions Weekly" describes an adult woman who showed lack of efficacy while being treated with quetiapine for delusions of infestation. The woman initially experienced mild chorea in her mid-40s, followed by cognitive decline, depression, and anxiety, leading to a diagnosis of Huntington's disease. Despite being switched from quetiapine to olanzapine and other medications, her delusions persisted until risperidone was introduced, resulting in resolution of the infestation. The woman also received various medications for insomnia throughout the treatment process. [Extracted from the article]

A woman in her 70s experienced lack of efficacy while being treated with various antidepressants for depression. Despite receiving multiple medications such as paroxetine, sertraline, fluoxetine, quetiapine, and olanzapine, she continued to have severe depressive episodes with cognitive impairment. Eventually, her treatment was switched to esketamine along with fluoxetine therapy, leading to improvement in her treatment-resistant depression and cognitive impairment. [Extracted from the article]

A 72-year-old man with a history of schizophrenia, Parkinson's disease, seizure disorder, and bipolar disorder developed SILENT syndrome while being treated with lithium and quetiapine. He presented with altered mental status and was found to have slurred speech and ataxia. After discontinuing his home medications and receiving interdisciplinary management, his mental status spontaneously improved and he was successfully discharged. The family remained hopeful throughout his treatment. [Extracted from the article]

A 29-year-old man experienced lethargy and dizziness while taking quetiapine for bipolar disorder and clarithromycin for an ear infection. The man's mental state improved with the use of quetiapine, but after starting clarithromycin, he became lethargic and dizzy. This was due to a drug interaction between quetiapine and clarithromycin, which increased the concentration of quetiapine in his system. The man's symptoms resolved after discontinuing the medications and receiving treatment for quetiapine metabolism. [Extracted from the article]

A 39-year-old man with schizophrenia experienced withdrawal symptoms in the form of tonic-clonic seizures after discontinuing carbamazepine and during treatment with quetiapine. He also exhibited lack of efficacy with multiple medications for both schizophrenia and hypertension. The man had a history of learning disability and difficulties in social relationships, and his symptoms worsened over time. After being admitted to the hospital, his medications were adjusted and he experienced some improvement in symptoms, although he did develop seizures after discontinuing carbamazepine. Overall, the case highlights the challenges of finding effective treatments for individuals with complex psychiatric conditions. [Extracted from the article]

A 36-year-old man experienced priapism while taking sildenafil for erectile dysfunction, as well as fluoxetine and quetiapine for depression. He also had a lack of efficacy with prophylactic antibiotic therapy and pseudoephedrine for priapism. The man underwent a procedure called Winter's shunt, but experienced recurrent priapism and developed a bilateral corpus cavernosum abscess. Despite receiving prophylactic antibiotic therapy, the abscess developed and Prevotella bivia was detected. The man's condition improved after surgery and he was discharged with a course of antibiotics. [Extracted from the article]

Two case reports were described in a study of 38,349 patients conducted between 1993 and 2016. The patients, who were diagnosed with schizophrenia, developed agranulocytosis while being treated with a combination of clozapine, mirtazapine, and quetiapine. One patient died as a result of agranulocytosis caused by clozapine and mirtazapine, while the other patient died due to agranulocytosis caused by clozapine and quetiapine. The dosages, routes, and duration of the treatments leading to these reactions were not stated. [Extracted from the article]

A 49-year-old woman experienced somnolence while being treated with quetiapine for functional neurological disorder (FND). She had a history of functional seizures, chronic pain, asthma, migraine, and bipolar disorder. The woman presented to the emergency department with altered mental status, aphasia, and paralysis. After a thorough examination and investigation, a diagnosis of FND was made. It was determined that the somnolence was likely a side effect of quetiapine, and the medication was discontinued. The woman showed significant improvement after discontinuation and was discharged home. [Extracted from the article]

A 79-year-old man with dementia and behavioral disturbance experienced a lack of efficacy with the medications memantine, quetiapine, buspirone, and sertraline. He was hospitalized due to acute-on-chronic altered mental status and difficulties with oral intake. The man exhibited hyperactive delirium and aggressive behavior, leading to the implementation of physical restraints. After adjusting his medication regimen, including stopping sertraline and buspirone and increasing quetiapine, the man's behavior improved, and he was discharged. However, he passed away 17 months later, and the cause of death was not specified. [Extracted from the article]

A 15-year-old girl was admitted to the pediatric intensive care unit (PICU) after overdosing on multiple drugs, including quetiapine, aspirin, bisoprolol, fluoxetine, furosemide, alprazolam, and pregabalin. She exhibited symptoms such as unresponsiveness, sluggish pupils, slow breathing, low blood pressure, and a pharmacobezoar. The girl underwent gastric lavage and endoscopic gastric decontamination to remove the ingested materials. After her stay in the PICU, she was transferred to the neuropsychiatric ward. [Extracted from the article]

An 18-year-old woman with a history of high-risk pre-B-cell acute lymphoblastic leukemia experienced lack of efficacy during treatment with dexamethasone, dexmedetomidine, and quetiapine for immune cell-effector associated neurotoxicity syndrome. Her condition worsened despite the medications, and she was transitioned to high-dose methylprednisolone. Other medications, such as olanzapine, melatonin, diazepam, and clonidine, were added to manage her symptoms. Eventually, her condition improved, and she was discharged with impaired language. [Extracted from the article]

A 30-year-old woman with a history of ulcerative colitis, depression, and a car wreck sought treatment for delayed sleep-wake phase disorder (DSWPD). She had previously been treated with melatonin, trazodone, and quetiapine, but experienced no improvement. After being diagnosed with DSWPD, she began a comprehensive treatment plan that included melatonin, light therapy, and cognitive behavioral therapy. While she showed some improvement in sleep training, there is still a need for increased education on sleep disorders in residency programs. [Extracted from the article]

A 69-year-old man developed aspiration pneumonia while being treated with quetiapine for manic depression and insomnia. He presented to the hospital with symptoms such as dyspnea, fever, drowsiness, and loss of appetite. Chest examinations and imaging revealed atelectasis and foreign body artifacts in the lungs. It was determined that the patient had aspirated a fragment of a denture, leading to bronchial obstruction and pneumonia. The man was treated with antibiotics and underwent surgery, resulting in improvement of the infection. [Extracted from the article]

In a study conducted between January 2018 and September 2020, a group of patients with bipolar depression who were treated with quetiapine (Bipresso) extended-release tablets experienced various side effects. These included somnolence, akathisia, dizziness, and severe suicidal ideation. The study did not provide specific information about the patients' ages, sexes, dosages, treatment durations, or outcomes. [Extracted from the article]

A 73-year-old man developed neuroleptic malignant syndrome while being treated with haloperidol and quetiapine for antipsychotic use. He presented to the emergency department with an acute change in mental status, including slurred speech, difficulty comprehending information, memory loss, headache, and difficulty walking. He was diagnosed with encephalopathy and admitted for further evaluation. The man was treated with various medications and supportive measures, and after four days, his symptoms resolved and he was transferred out of the ICU. His behavioral symptoms were stabilized with donepezil and quetiapine. [Extracted from the article]

A 34-year-old man with bipolar disorder and intellectual disability experienced gastrointestinal hypomotility and lack of efficacy while taking clozapine, quetiapine, and benzatropine. He was admitted to the hospital with worsening bipolar symptoms and received senna-alexandrina for constipation. After starting clozapine, he developed severe gastrointestinal symptoms and was admitted to the ICU with septic shock. Treatment with antibiotics, bowel rest, and other interventions led to his recovery. The authors concluded that the interaction between the three medications caused the gastrointestinal issues. [Extracted from the article]

A 27-year-old man with schizophrenia exhibited a lack of efficacy during treatment with multiple antipsychotic drugs, including risperidone, quetiapine, olanzapine, haloperidol, and amisulpride. Despite receiving these medications, his condition did not improve. He was then treated with clozapine and aripiprazole, which resulted in some improvement after six months. This case suggests that the patient's schizophrenia was refractory to the initial medications but responded to the subsequent treatment. [Extracted from the article]

A 48-year-old man with schizophrenia experienced sedation, thinking impairment, sialorrhoea (excessive saliva production), and walking disability while being treated with clozapine and quetiapine. The man had a history of hospitalizations for psychotic episodes but had been asymptomatic since 2013 while on the medication regimen. He denied substance abuse and reported reducing his tobacco use. The symptoms were determined to be a result of the clozapine and quetiapine, and the man's dosage was gradually reduced, leading to the disappearance of the symptoms. He was subsequently discharged. [Extracted from the article]

A 27-year-old man with schizophrenia exhibited a lack of efficacy during treatment with multiple drugs, including risperidone, quetiapine, olanzapine, haloperidol, and amisulpride. He was hospitalized due to significant behavioral and cognitive disorganization. Despite receiving these medications, there was no improvement in his condition, suggesting that his schizophrenia was refractory to these drugs. He later received treatment with clozapine and aripiprazole, which resulted in improvement and allowed him to resume his studies. [Extracted from the article]

A 48-year-old man with schizophrenia experienced sedation, thinking impairment, sialorrhoea (excessive saliva production), and walking disability while being treated with clozapine and quetiapine. The man had a history of hospitalizations for psychotic episodes but had been asymptomatic since 2013 while on the medication regimen. He denied substance abuse and reported reducing his tobacco use. The symptoms were determined to be a result of the clozapine and quetiapine, and the man's dosage was gradually reduced, leading to the disappearance of the symptoms. He was subsequently discharged. [Extracted from the article]

An approximately 17-year-old girl developed worsening catatonia while being treated with quetiapine and olanzapine for psychosis. She had previously been diagnosed with antibody negative autoimmune encephalitis and had received corticosteroids and immune globulin, which improved her symptoms. After experiencing worsening catatonia, she was treated with lorazepam, plasmapheresis, rituximab, methylprednisolone-sodium-succinate, and electroconvulsive therapy, which significantly improved her condition. However, when she was given low-dose antipsychotic treatment with quetiapine and olanzapine, her catatonia worsened again. She received further electroconvulsive therapy and her catatonia continued to improve. [Extracted from the article]

A 47-year-old woman with bipolar I disorder experienced sedation while taking quetiapine, an on and off phenomenon while taking lorazepam, and exhibited treatment non-compliance with quetiapine and lamotrigine. She had a history of hospitalizations for manic episodes and severe major depressive disorder. Her symptoms worsened, including mood swings, anxiety, irritability, poor sleep, and paranoia. She stopped taking her medications and exhibited symptoms of withdrawal, restlessness, and thought perseveration. Treatment with lorazepam improved her symptoms, but she refused to continue due to concerns about dependency and sedation. The dose of quetiapine was increased, but sedation became an issue, so she was switched to risperidone and lorazepam for mood stabilization. [Extracted from the article]

A 13-year-old girl with tic cough was treated with escitalopram and quetiapine, but experienced lack of efficacy. She also developed sleepiness when aripiprazole was added to her treatment. The girl had a medical history of congenital hydrocephalus and underwent surgical treatment two years prior. After three months of therapy, there was no improvement in her tic cough, indicating lack of efficacy. However, after undergoing intensive psychotherapy and discontinuing aripiprazole, her cough gradually reduced and subsided, leading to complete remission. [Extracted from the article]

A 39-year-old man developed hyperprolactinaemia while being treated for schizophrenia with quetiapine and haloperidol. He had a pituitary macroadenoma and was diagnosed with macroprolactinoma. He was initially started on cabergoline, which was later adjusted. In 2016, he started experiencing hallucinations and depression and was prescribed quetiapine and haloperidol. However, he developed hyperprolactinaemia as a result of these medications, as well as irregular use of cabergoline. In 2020, he also developed central hypothyroidism and was started on levothyroxine-sodium. [Extracted from the article]

A 60-year-old woman experienced somnolence while being treated with lorazepam for nightmare and anxiety disorder. She also did not respond well to quetiapine for nightmares, anxiety disorder, and agoraphobia. The woman had a history of breast cancer, anxiety disorder, and agoraphobia, and had previously undergone surgery for necrotising fasciitis. After being referred to a different hospital, her nightmares were successfully resolved with the initiation of prazosin, and her anxiety disorder was well-controlled with duloxetine. [Extracted from the article]

This article discusses a case series of five women aged 51-68 who developed hyponatremia (low sodium levels) while being treated with vasopressin, gabapentin, or quetiapine for vasospasm. The cases describe the patients' medical histories, symptoms, and treatments. In each case, the patients' serum sodium levels decreased during vasopressin infusion but increased after discontinuation and alternative treatments. The article highlights the potential risk of hyponatremia associated with these medications and emphasizes the importance of monitoring sodium levels during treatment. [Extracted from the article]

A retrospective cohort study was conducted on 13 adult patients who experienced QRS complex widening after overdosing on bupropion, a medication used for various indications. The patients ingested different dosages of bupropion, with some also co-ingesting other substances. Following the overdose, all patients required hospital admission due to QRS complex prolongation, and they were treated with sodium-bicarbonate. The study provides information on the occurrence of QRS complex widening as a result of bupropion overdose. [Extracted from the article]

A 10-year-old boy named Jaun experienced withdrawal emergent syndrome (WES) after stopping the medication haloperidol for agitation. He also showed a lack of efficacy when treated with quetiapine for agitation. Jaun, who had post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), and reactive attachment disorder, was admitted to the hospital after swallowing a magnet. His treatment initially included olanzapine and aripiprazole, but was later switched to quetiapine and haloperidol. While his behavior improved, he experienced worsened symptoms after taking quetiapine, leading to its discontinuation. Haloperidol was also stopped, but Jaun was later diagnosed with WES and restarted on a tapered dose of haloperidol, which he tolerated well without recurrence of WES. [Extracted from the article]

A 13-year-old boy developed Ekbom syndrome and experienced weight gain while being treated for bipolar-I disorder with lithium and quetiapine. The boy exhibited symptoms such as hyperactivity, decreased need for sleep, mood swings, and delusions. After further evaluation, he was diagnosed with bipolar-I disorder and started receiving lithium, which resulted in a dystonic syndrome. The boy was then switched to quetiapine, which successfully controlled his manic symptoms but caused weight gain. After 16 weeks, he was in remission. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 76-year-old man exhibited lack of efficacy with quetiapine, haloperidol and off-label dexamethasone, while being treated for delirium and COVID-19, respectively [routes and dosages not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA man in his 20s [exact age not stated] developed unwanted daytime sedation, low libido, feelings of apathy, increasing low mood, worsening of stimulant craving and worsening stimulant (substance) use disorder during empiric treatment with aripiprazole and quetiapine [not all dosages and outcomes stated; durations of treatments to reactions onset not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 25-year-old man developed dental irregularity, osteoporosis and alveolar bone defect during treatment with fluvoxamine, quetiapine and alprazolam for anxiety disorder. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 34-year-old man developed hypertriglyceridaemia, diabetes mellitus, diabetic ketoacidosis and acute pancreatitis during treatment with quetiapine for bipolar disorder and schizophrenia [route, dosage and duration of treatment to reactions onsets not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 27-year-old man developed thrombotic microangiopathy during treatment with quetiapine for schizoaffective disorder and depression. [Extracted from the article]

A case report published in Reactions Weekly describes a female patient who experienced QT prolongation after self-poisoning with quetiapine and levomepromazine. The patient had also been exposed to Taxus baccata (yew) and was admitted to the hospital. The report does not provide specific details about the amount ingested, the time it took for the reaction to occur, or the outcome of the patient. This information is based on a retrospective observational study of 11 patients between May 2012 and May 2020. [Extracted from the article]

A 64-year-old woman experienced peripheral edema while being treated with quetiapine for bipolar disorder. This was accompanied by an increase in quetiapine concentration due to a drug-drug interaction with valproate. The woman also displayed treatment non-compliance and drug misuse while being treated with paliperidone for bipolar disorder. The specific details regarding the administration of the treatments, the timing of the reactions, and the outcome were not provided. [Extracted from the article]

A 71-year-old woman experienced diarrhea while taking donepezil and lower extremity edema while taking risperidone for dementia. She also did not respond well to memantine and quetiapine for dementia. The woman had a history of multiple chronic conditions and a family history of alcoholism. Her symptoms improved with risperidone but she developed edema, which resolved after stopping the medication. She later restarted quetiapine for agitation. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventAn 84-year-old woman developed severe hypoglycaemia during treatment with quetiapine [indication not stated]. [Extracted from the article]

A 64-year-old man with intellectual disability experienced various toxicities and off-label use of medications. He was being treated with risperidone, quetiapine, and levomepromazine for his intellectual disability, as well as off-label treatment with oxcarbazepine for impulsivity. However, he developed stiffness, hyperphagia, and auto-aggressiveness as a result of the treatment. After discontinuing oxcarbazepine, his symptoms rapidly improved and his serum sodium levels returned to normal. [Extracted from the article]

In a case series of 3 women, a 35-year-old pregnant woman experienced excessive sedation while being treated with quetiapine for complex posttraumatic stress disorder (CPTSD). The woman initially refused medication until after giving birth, and her pregnancy was complicated by gestational diabetes. She was prescribed quetiapine but stopped taking it after 3 days due to excessive sedation. She was then prescribed sertraline, which she found helpful but had intermittent adherence. The woman was lost to follow-up at 10 months postpartum. [Extracted from the article]

A 51-year-old man developed delusional parasitosis after abusing fentanyl and metamfetamine. He was also found to have a lack of efficacy when treated with quetiapine for his condition. The man had a history of substance abuse, including alcohol, fentanyl, and metamfetamine, and had previously received quetiapine for suspected bipolar depression. He experienced tactile and visual hallucinations, which were believed to be caused by his substance abuse. He was admitted to a psychiatric unit and treated with quetiapine, but showed no improvement until he was switched to haloperidol. After 19 days of hospitalization, he was discharged on haloperidol and a reduced dose of quetiapine. In subsequent visits, his delusional parasitosis symptoms were not noted, suggesting that they had resolved. [Extracted from the article]

In a retrospective study involving 81 adult patients, two cases were reported of drug intoxication resulting in death. The patients were admitted to a hospital in Croatia and had been treated with various medications including promazine, clozapine, buprenorphine, ziprasidone, alprazolam, pregabalin, and quetiapine. The specific dosages, routes of administration, and indications for these medications were not provided. The study highlights the serious consequences of drug intoxication and the need for further research in this area. [Extracted from the article]

A 68-year-old man developed neuroleptic malignant syndrome (NMS) while being treated with memantine, quetiapine, and rivastigmine for an unspecified psychiatric disorder. He presented with symptoms such as shortness of breath, vomiting, cough, disorientation, irritability, and muscle rigidity. The patient had a medical history of diabetes, hypertension, coronary artery disease, oesophagitis with duodenal ulcer, hiatal hernia, and chronic kidney disease. The NMS was determined to be related to the psychiatric therapy, and the patient was treated with bromocriptine and baclofen, resulting in mild improvement. [Extracted from the article]